These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Lipid-lowering agents for concurrent cardiovascular and chronic kidney disease. Katsiki N; Mikhailidis DP; Banach M Expert Opin Pharmacother; 2019 Nov; 20(16):2007-2017. PubMed ID: 31344332 [No Abstract] [Full Text] [Related]
4. Impact of Blood or Erythrocyte Membrane Fatty Acids for Disease Risk Prediction: Focusing on Cardiovascular Disease and Chronic Kidney Disease. Kim OY; Lee SM; An WS Nutrients; 2018 Oct; 10(10):. PubMed ID: 30301276 [TBL] [Abstract][Full Text] [Related]
5. Regulation of platelet function and thrombosis by omega-3 and omega-6 polyunsaturated fatty acids. Adili R; Hawley M; Holinstat M Prostaglandins Other Lipid Mediat; 2018 Nov; 139():10-18. PubMed ID: 30266534 [TBL] [Abstract][Full Text] [Related]
6. The role of omega-3 polyunsaturated fatty acids in cardiovascular health. Barrett SJ Altern Ther Health Med; 2013; 19 Suppl 1():26-30. PubMed ID: 23981464 [TBL] [Abstract][Full Text] [Related]
7. Omega-3 fatty acid supplementation changes intracellular phospholipase A2 activity and membrane fatty acid profiles in individuals at ultra-high risk for psychosis. Smesny S; Milleit B; Hipler UC; Milleit C; Schäfer MR; Klier CM; Holub M; Holzer I; Berger GE; Otto M; Nenadic I; Berk M; McGorry PD; Sauer H; Amminger GP Mol Psychiatry; 2014 Mar; 19(3):317-24. PubMed ID: 23478748 [TBL] [Abstract][Full Text] [Related]
8. Omega-3 polyunsaturated fatty acids: anti-inflammatory and anti-hypertriglyceridemia mechanisms in cardiovascular disease. Shibabaw T Mol Cell Biochem; 2021 Feb; 476(2):993-1003. PubMed ID: 33179122 [TBL] [Abstract][Full Text] [Related]
9. ω3-Polyunsaturated fatty acids for heart failure: Effects of dose on efficacy and novel signaling through free fatty acid receptor 4. O'Connell TD; Block RC; Huang SP; Shearer GC J Mol Cell Cardiol; 2017 Feb; 103():74-92. PubMed ID: 27986444 [TBL] [Abstract][Full Text] [Related]
10. Do B Vitamins Enhance the Effect of Zhu J; Xun PC; Kolencik M; Yang KF; Fly AD; Kahe K Nutrients; 2022 Apr; 14(8):. PubMed ID: 35458173 [TBL] [Abstract][Full Text] [Related]
12. Higher ratio of plasma omega-6/omega-3 fatty acids is associated with greater risk of all-cause, cancer, and cardiovascular mortality: A population-based cohort study in UK Biobank. Zhang Y; Sun Y; Yu Q; Song S; Brenna JT; Shen Y; Ye K Elife; 2024 Apr; 12():. PubMed ID: 38578269 [TBL] [Abstract][Full Text] [Related]
13. Differential dose effect of fish oil on inflammation and adipose tissue gene expression in chronic kidney disease patients. Guebre-Egziabher F; Debard C; Drai J; Denis L; Pesenti S; Bienvenu J; Vidal H; Laville M; Fouque D Nutrition; 2013 May; 29(5):730-6. PubMed ID: 23375525 [TBL] [Abstract][Full Text] [Related]
14. Plasma and erythrocyte membrane phospholipids and fatty acids in Italian general population and hemodialysis patients. Dessì M; Noce A; Bertucci P; Noce G; Rizza S; De Stefano A; Manca di Villahermosa S; Bernardini S; De Lorenzo A; Di Daniele N Lipids Health Dis; 2014 Mar; 13():54. PubMed ID: 24655786 [TBL] [Abstract][Full Text] [Related]
15. Effects of omega-3 polyunsaturated fatty acids on cardiac myocyte protection. Bei R; Frigiola A; Masuelli L; Marzocchella L; Tresoldi I; Modesti A; Galvano F Front Biosci (Landmark Ed); 2011 Jan; 16(5):1833-43. PubMed ID: 21196268 [TBL] [Abstract][Full Text] [Related]
16. n-3 Polyunsaturated fatty acids for the management of alcoholic liver disease: A critical review. Wang M; Ma LJ; Yang Y; Xiao Z; Wan JB Crit Rev Food Sci Nutr; 2019; 59(sup1):S116-S129. PubMed ID: 30580553 [TBL] [Abstract][Full Text] [Related]
17. Effects of N-3 PUFAs supplementation on insulin resistance and inflammatory biomarkers in hemodialysis patients. Rasic-Milutinovic Z; Perunicic G; Pljesa S; Gluvic Z; Sobajic S; Djuric I; Ristic D Ren Fail; 2007; 29(3):321-9. PubMed ID: 17497447 [TBL] [Abstract][Full Text] [Related]
18. Omega 3 fatty acids in cardiovascular disease risk factors: An updated systematic review of randomised clinical trials. Rangel-Huerta OD; Gil A Clin Nutr; 2018 Feb; 37(1):72-77. PubMed ID: 28601400 [TBL] [Abstract][Full Text] [Related]
19. Variability in the Clinical Effects of the Omega-3 Polyunsaturated Fatty Acids DHA and EPA in Cardiovascular Disease-Possible Causes and Future Considerations. Michaeloudes C; Christodoulides S; Christodoulou P; Kyriakou TC; Patrikios I; Stephanou A Nutrients; 2023 Nov; 15(22):. PubMed ID: 38004225 [TBL] [Abstract][Full Text] [Related]
20. Cardiovascular Diseases and Marine Oils: A Focus on Omega-3 Polyunsaturated Fatty Acids and Polar Lipids. Caffrey C; Leamy A; O'Sullivan E; Zabetakis I; Lordan R; Nasopoulou C Mar Drugs; 2023 Oct; 21(11):. PubMed ID: 37999373 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]